INOVIO to Present at Upcoming Scientific Conference


PLYMOUTH MEETING, Pa., July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts. The conference brings together industry leaders and innovators in the rare disease space to explore the latest developments in technology and manufacturing.

(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

Orphan Drug Summit
Boston, MA
Date: July 16
Time: 4:30-4:55pm ET
Presentation: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302499023.html

SOURCE INOVIO Pharmaceuticals, Inc.

Werbung

Inovio Pharmaceuticals Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Inovio Pharmaceuticals nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
15.02.18 Inovio Pharmaceuticals Buy Maxim Group
18.10.17 Inovio Pharmaceuticals Outperform RBC Capital Markets
24.05.17 Inovio Pharmaceuticals Buy Maxim Group
16.03.17 Inovio Pharmaceuticals Buy Maxim Group
07.11.16 Inovio Pharmaceuticals Buy Aegis Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.